Lenoir, NC February 6, 2023 – Exela Pharma Sciences, LLC (“Exela”) has commenced patent infringement litigation today against Nivagen Pharmaceuticals, Inc. (“Nivagen”) in the United States District Court for the District of Delaware to prevent unauthorized launch of its recently approved 7.25% L-Cysteine injection drug product. Exela believes Nivagen’s product infringes one or more of Exela’s patents covering Exela’s pioneering work in developing low-aluminum L-Cysteine injection products. Exela seeks among other remedies a temporary restraining order and an injunction.
About Exela Pharma Sciences
Exela Pharma Sciences, a fast-growing US based integrated specialty pharmaceutical company, focuses on developing, manufacturing and marketing proprietary and generic sterile injectable products with the healthcare provider and patient in mind. Our goal is to deliver high quality, affordable products that make a difference in people’s lives and meet the needs of the healthcare providers that treat them. Built from a strong Research and Development, Regulatory and Quality foundation, Exela is focused on delivering excellence in Quality, Reliability and Affordability. Established in 2005 by a former Pharmacist, Exela receives awards for its supply chain commitment and dedication to creating hundreds of high value jobs in rural America. All of Exela’s development and manufacturing operations are in Lenoir, North Carolina. Please visit www.exelapharma.com to learn more.
For more information, contact Mark Hartman at mhartman@exela.us.